/ WHAT YOU WILL RECEIVE
Real photographs of your peptides, boxed, lot-labeled, and shipped in plain unmarked packaging from our partner research lab.
More batch photos and lab footage coming soon.
PEPTIDE SEQUENCE · STRUCTURE NOTE
Y-Aib-QGTFTSDYSILLDKKAQ-Aib-AFIEYLLEGGPSSGAPPPS-NH2
Triple agonist (GLP-1 / GIP / Glucagon) with C20 fatty acid chain conjugated to Lys.
⏱ HALF-LIFE · PHARMACOKINETIC PROFILE
Triple agonist (GLP-1 / GIP / Glucagon)
5 to 7 days
Long-acting backbone with C20 fatty-acid chain, designed for once-weekly research dosing.
GLP-1s · RESEARCH GRADE
Retatrutide
30mg · Lyophilized Vial · Triple Agonist
SELECT DOSAGE
Triple agonist (GLP-1 / GIP / Glucagon), high-capacity 30mg vial for extended protocols.
UNIT PRICE
$89 USD
≈ CA$124
Reconstitution required
This compound requires bacteriostatic water for reconstitution. Don't forget to add a 10mL vial of BAC water to your order, available in Lab Supplies.
HOW LONG WILL IT LAST YOU?
Enter your research protocol and vial quantity — see exactly how many weeks your order covers.
Each 30mg vial lasts
15 weeks
Your 30mg vial lasts
15weeks
≈ 105 days · 15 doses per vial
FOR RESEARCH USE ONLY
Not for human consumption. Intended for laboratory and in-vitro research applications./ BUNDLE & SAVE · AGGRESSIVE PRICING
Stack up.
Save big.
Flat bundle prices on 30mg Retatrutide. Discounts apply automatically at the cart.
Save 0% · Mix & match any dosage
Save 0% · Most researchers choose this
Save 0% · Max-research economy
/ RESEARCH DOSSIER
Everything we know
about Retatrutide.
Direct from the research literature. Every section is sourced from peer-reviewed peptide studies and clearly labelled when effects come from animal or cell-line models.
/ 01 · WHAT WE KNOW
The background.
Retatrutide is a triple-receptor agonist activating GLP-1, GIP, and glucagon receptors. Phase 2 clinical research shows the most substantial body-weight effects observed in any incretin research to date.
/ 02 · WHAT IT DOES FOR YOU
What researchers study it for.
Under investigation for advanced metabolic, hepatic, and body composition research. Glucagon arm adds basal energy expenditure beyond GLP-1/GIP pathways. 30mg capacity supports multi-week titration studies without mid-protocol re-order.
RESEARCH HIGHLIGHTS · published animal & cell-model studies
- ▸Phase 2 weight-loss trials reported sustained reductions in body weight beyond GLP-1-monotherapy baselines
- ▸Improved glycemic markers in T2D research populations
- ▸Notable adipose-tissue lipolysis observed at higher dose tiers
- ▸Tolerability profile broadly comparable to other long-acting incretins at equivalent escalation
Sourced from peer-reviewed research literature. Effects described are from animal & cell-line models unless otherwise noted. For research use only.
/ 03 · HOW IT WORKS
Mechanism of action.
Biological pathways identified in the research literature for Retatrutide.
Activates GLP-1 receptors → enhanced glucose-dependent insulin secretion + delayed gastric emptying
Activates GIP receptors → potentiated insulinotropic effect + adipose-tissue signaling
Activates glucagon receptors → upregulated hepatic energy expenditure and lipid oxidation
Triple synergy produces appetite-suppression and energy-expenditure effects exceeding single- or dual-agonists
/ 04 · OVERVIEW & CLASSIFICATION
Classification.
Retatrutide is a synthetic 39-residue triple-incretin analog (GLP-1 / GIP / glucagon receptor agonist) under late-stage research as the next-generation incretin therapeutic.
TYPE
Triple-agonist peptide
DERIVATION
Synthetic, solid-phase peptide synthesis with C20 fatty-diacid conjugation for albumin binding.
STRUCTURE
39-aa modified GIP backbone with substitutions enabling balanced activity at GLP-1R, GIPR, and GCGR.
/ 05 · PHARMACOLOGICAL PROFILE
Pharmacology.
HALF-LIFE
~6 days (once-weekly dosing supported)
ABSORPTION
Subcutaneous absorption; albumin-binding extends serum residency
DISTRIBUTION
Predominantly extracellular, minimal CNS penetration
/ 06 · DOSAGE & RECONSTITUTION
Research dosing protocols.
/ 07 · PAIRS WELL WITH
Researched stacks.
Compounds explored alongside Retatrutide in the published literature.
Tirzepatide
Parallel protocol comparison of triple vs dual agonism, allows researchers to isolate glucagon-receptor contribution.
/ 08 · SAFETY PROFILE
Safety notes.
- ▸GI: nausea, decreased appetite, delayed gastric emptying, dose-dependent
- ▸Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndromes (research caution)
- ▸Hypoglycemia risk low as monotherapy; elevates with concomitant insulin or sulfonylurea
- ▸Always follow institutional protocols and IRB/IACUC requirements
Research use only · not for human consumption · always consult published literature before designing any research protocol.